Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Six pharma stocks that should be on your radar today over various news triggers
It was a busy weekend for pharma stocks as four of them — Divi's Laboratories, Fortis Healthcare, Torrent Pharma and Narayana Hrudayalaya — reported their quarterly results. Meanwhile, Lupin marked its entry into the Chinese market, while Glenmark Pharma's US arm settled an anti-trust litigation. Here's a look at these names in detail:
Ahead of Market: 10 things that will decide stock market action on Monday
Indian equity benchmarks closed modestly higher on Friday, with financial stocks leading the gains. The Nifty and Sensex edged up, though pharma and healthcare weakness capped the rise. Analysts noted the market's indecisive range-bound movement, awaiting a decisive breakout above 23,800 for further upward momentum or a fall towards 23,600.
6 pharma stocks that Bernstein sees up to 40% upside potential. Do you own any?
Bernstein initiated coverage on six pharma stocks, expressing a positive outlook on the Indian healthcare sector driven by AI, innovation in niche areas, and a strengthening ecosystem. The brokerage highlighted attractive valuations and easing policy uncertainties, naming Zydus Lifesciences as its top pick with a significant upside potential.
Sakar Healthcare partners with Zydus Lifesciences for GCC Markets
Sakar Healthcare has partnered with Zydus Lifesciences to supply oncology products in GCC countries and other emerging markets. This marks the company's 40th global agreement in the anti-cancer segment. Sakar Healthcare is expanding its international oncology business and strengthening its presence in emerging markets. The company is also progressing with regulatory filings and approvals in highly regulated markets.
Kerala’s healthcare gold rush: How private equity is reshaping hospitals and raising fears over costs
Private equity funds are pouring hundreds of millions of dollars into Kerala’s healthcare sector, reshaping a system long dominated by independent doctors and family-run hospitals.
Fortis Healthcare consolidated net profit rises 44.57% in the March 2026 quarter
Sales rise 17.81% to Rs 2364.67 crore
Fortis liability case: Delhi HC says blame can't be shifted to third party
Amid ongoing legal disputes, the Delhi High Court is probing Fortis Healthcare's oversight concerning the sale of shares belonging to the Singh brothers, former promoters of the company. The court's remarks suggest that Fortis had a responsibility to inhibit such transactions.
Cotec Healthcare, Deepa Jewellers receive SEBI's nod to float IPOs
Cotec Healthcare and Deepa Jewellers get SEBI approval for IPOs, plan fresh issues and OFS to fund capacity expansion, working capital and general corporate needs, to list on BSE and NSE
Fortis Healthcare Q4 profit up 45% on lower exceptional losses, higher revenue
The board recommended a final dividend of ₹1 per equity share of face value ₹10 each for FY26. Shares of Fortis Healthcare Limited ended ₹5.40 lower at ₹961.90 on the NSE today, May 22.
Pharma, healthcare stocks drag markets amid volatility; Nifty and Sensex close week in green
The equity benchmark indices closed in the green on Friday (May 22) but could not fully hold intraday gains, with Sensex rising 232 points to 75,415 and Nifty gaining 65 points to 23,719.
Q4 Results Live Updates: Sun Pharma Revenue Up 12%; IRCON Profit Falls 10%
Key companies in focus include Sun Pharma, NTPC Green Energy, Hindalco Industries, Eicher Motors, Colgate-Palmolive (India), Fortis Healthcare and 3M India.
Engineers India Ltd leads losers in 'A' group
Ganesha Ecosphere Ltd, Central Bank of India, Max Healthcare Institute Ltd and GMR Power & Urban Infra Ltd are among the other losers in the BSE's 'A' group today, 22 May 2026.